Immunovant (IMVT)
(Delayed Data from NSDQ)
$27.17 USD
-0.58 (-2.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.13 -0.04 (-0.15%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
IMVT 27.17 -0.58(-2.09%)
Will IMVT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IMVT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMVT
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
What Makes Immunovant (IMVT) a New Buy Stock
IMVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks
Other News for IMVT
June 7th Options Now Available For Immunovant (IMVT)
Immunovant (IMVT) Gets a Buy from Piper Sandler
Immunovant management to meet with Piper Sandler
Baron Health Care Fund Q1 2024 Shareholder Letter
3 Best Stocks to Buy Now, 4/22/2024, According to Top Analysts